DHR · News · 20261107N

Regulatory Approval Milestones

DANAHER CORP /DE/ · 2026-11-07 · Importance 31 · Surprise 42

The U.S. Food and Drug Administration cleared Cepheid’s four-virus hemorrhagic fever panel on November 7, 2026. The test runs on Danaher’s GeneXpert system, extending the platform’s diagnostic applications. The report provides no financial impact estimate or launch timeline.

Key facts

• Danaher's Cepheid diagnostics unit received FDA clearance for a four-virus hemorrhagic fever panel. source